Marjaan General Trading

Marjaan General Trading, established in 2011 and headquartered in Ajman, United Arab Emirates, is a prominent B2B wholesale supplier specializing in customized products such as uniforms, safety wear, kidswear, fragrances, and Umrah essentials. The company serves a diverse clientele, including businesses, institutions, retailers, and resellers across the UAE and beyond, emphasizing quality products and dependable service.

While Marjaan General Trading's primary focus is on the wholesale supply of customized products, it has also engaged in the importation of pharmaceutical formulations from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $105,000 USD, comprising 405 shipments. These imports included 1,578 unique formulations across three therapeutic categories, with Ayurvedic and Herbal Products accounting for 100% of the imports. The top three products imported were Taila ($88,000 USD), Arishta ($14,000 USD), and Ghrita ($3,000 USD). The primary suppliers for these products were KELY EXPORTS AND IMPORTS and KELY EXPORTS IMPORTS, accounting for 74.8% and 25.2% of the total import value, respectively.

Marjaan General Trading operates from its warehouse located at 25/14, 61 Street, Ajman Industrial 1, Ajman, UAE. (2gis.ae) The company has developed a robust logistics network to support its wholesale operations, ensuring efficient distribution of its diverse product range across the UAE and to international markets. While specific details about its distribution channels are not publicly disclosed, Marjaan's emphasis on fast and flexible supply chains indicates a well-organized logistics framework capable of meeting the demands of its varied clientele.

In the pharmaceutical supply chain within the UAE, Marjaan General Trading functions as an importer and distributor, focusing on Ayurvedic and Herbal Products sourced from India. The company's role involves importing finished pharmaceutical formulations and distributing them to various stakeholders, including businesses, institutions, and retailers. This positions Marjaan as a key player in the niche market of Ayurvedic and Herbal pharmaceutical products, catering to the growing demand for alternative medicine options in the UAE.

Marjaan General Trading's sourcing strategy exhibits a high degree of concentration, with 100% of its pharmaceutical imports originating from two suppliers: KELY EXPORTS AND IMPORTS and KELY EXPORTS IMPORTS. This dual-supplier model suggests a strategic choice to maintain strong, focused relationships with key suppliers, potentially ensuring consistency in product quality and supply reliability. However, the lack of diversification in sourcing could pose risks, such as supply chain disruptions or price fluctuations. The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent import volumes over the years. Nonetheless, the absence of alternative suppliers may limit Marjaan's ability to negotiate better terms or adapt to market changes swiftly.

Marjaan General Trading's supply chain resilience appears to be moderate. The company's reliance on two primary suppliers for its pharmaceutical imports suggests a focused approach but also indicates potential vulnerabilities. The absence of backup suppliers could lead to challenges in the event of supply disruptions. Additionally, the limited diversity in imported formulations, with 1,578 unique formulations across three therapeutic categories, may restrict the company's ability to adapt to changing market demands. The shipping routes from India to the UAE are well-established, but any geopolitical or logistical issues could impact supply continuity. Regarding regulatory compliance, the key suppliers are expected to adhere to international standards, but specific certifications are not detailed in the available data.

Marjaan General Trading's concentrated sourcing strategy positions it to leverage strong relationships with its suppliers, potentially ensuring product consistency and favorable terms. However, this approach also exposes the company to risks associated with supply chain disruptions and market fluctuations. For Indian exporters, the existing supplier relationships may present challenges in entering the market through Marjaan. To become alternative suppliers, Indian exporters would need to demonstrate superior product quality, competitive pricing, and the ability to meet the specific demands of the UAE market. Diversifying Marjaan's supplier base could enhance its supply chain resilience and provide more options to meet market needs.

The Emirates Drug Establishment (EDE), established in 2023, is the federal authority overseeing the regulation of pharmaceuticals and medical goods in the UAE. EDE's responsibilities include product approvals, surveillance, and ensuring regulatory compliance within the pharmaceutical sector. Prior to the establishment of EDE, the Ministry of Health and Prevention (MOHAP) was the primary regulatory body governing pharmaceutical products in the UAE. The regulatory framework is designed to ensure that all pharmaceutical products meet the country's quality, safety, and efficacy standards before they can be imported, distributed, or sold in the local market.

Importing pharmaceutical products into the UAE requires the importer to be licensed by the EDE. Only medical stores legally authorized by EDE can import and distribute medicines; medical warehouses can only store, not distribute or sell. Importers must obtain permits from EDE for each shipment, and the documentation includes a Certificate of Analysis (COA), Free Sale Certificate (FSC), Good Manufacturing Practice (GMP) certificate, bills of lading, and packing lists.

Pharmaceutical products imported into the UAE must undergo batch testing to ensure they meet the country's quality standards. Stability requirements are enforced to guarantee that products remain effective throughout their shelf life. Labeling must be in Arabic, and serialization mandates are in place to track and trace products throughout the supply chain, enhancing transparency and safety.

In 2024, the UAE introduced Federal Decree-Law No. 38, which established the Emirates Drug Establishment (EDE) as the central regulatory authority for all matters related to pharmaceuticals. This law introduced new requirements for companies importing products into the UAE, including the need for the Marketing Authorization Holder (MAH) to collaborate with two or more pharmaceutical establishments for importing and marketing medical products. The supporting regulations for this law have yet to be published, leaving some ambiguity regarding its practical application.

Marjaan General Trading's focus on Ayurvedic and Herbal Products aligns with the growing demand for alternative medicine options in the UAE. The imports of Taila, Arishta, and Ghrita suggest a strategic emphasis on traditional remedies that cater to a niche market segment. This product strategy is likely driven by consumer interest in natural and holistic health solutions, as well as the cultural significance of Ayurvedic practices in the region.

Marjaan General Trading's sourcing strategy for pharmaceutical products is centered on importing finished formulations from India, particularly Ayurvedic and Herbal Products. The company's reliance on two primary suppliers indicates a focused approach to procurement, aiming to maintain strong supplier relationships and ensure product consistency. India's established reputation in the production of Ayurvedic medicines positions it as a key supplier for Marjaan's sourcing needs.

Based on its product mix, Marjaan General Trading serves the niche segment of the UAE market that seeks Ayurvedic and Herbal pharmaceutical products. The company's imports are likely distributed through wholesale channels to businesses, institutions, and retailers that cater to consumers interested in alternative medicine options. This positioning allows Marjaan to tap into a growing market segment that values natural and traditional health solutions.

There is a realistic opportunity for new Indian suppliers to enter the UAE market through Marjaan General Trading. To do so, they would need to offer high-quality products that meet UAE regulatory standards, competitive pricing, and the ability to supply formulations that align with Marjaan's product strategy. Gaps in Marjaan's current sourcing include a limited diversity of formulations and a concentrated supplier base. New suppliers could address these gaps by providing a broader range of products and establishing alternative supply channels, thereby enhancing Marjaan's supply chain resilience.

Indian exporters seeking to supply Marjaan General Trading and the UAE market must ensure that their pharmaceutical products are registered with the Emirates Drug Establishment (EDE) and comply with UAE regulatory standards. Products must undergo batch testing, meet stability requirements, and adhere to labeling mandates in Arabic. Additionally, exporters must provide necessary documentation, including Certificates of Analysis, Free Sale Certificates, and Good Manufacturing Practice (GMP) certificates.

Indian exporters should initiate contact with Marjaan General Trading by presenting their product portfolios, emphasizing compliance with UAE regulatory standards, and highlighting the quality and efficacy